MetaCap

Oruka Therapeutics (ORKA) vs Achieve Life Sciences (QUIT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Oruka Therapeutics is the larger company by market cap ($6.50 billion vs $573.2 million), about 11.3 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ORKA-14.96%QUIT-25.87%
+16%-11%-39%
Aug 17, 20261 yearNov 20, 2026
ORKA-11.25%QUIT-30.41%
+8%-14%-35%
Aug 17, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ORKA versus QUIT key metrics
MetricORKAQUIT
Share price$95.81$5.56
Market cap$6.50B$573.25M
1-day change-1.80%-5.28%
YTD return+216.10%—
1-year return+227.11%—
5-year return+205.91%—
EPS (TTM)$-2.12$-1.71
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-105.43M$-54.65M
52-week high$115.52$8.64
52-week low$25.23$2.62
Distance from 52-week high-17.06%-35.65%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+63.00%+162.23%
Average volume965.27K1.38M
Shares outstanding67.82M103.10M
Employees6828
SectorHealth CareHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic SubstancesBiotechnology: In Vitro & In Vivo Diagnostic Substances

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Oruka Therapeutics is about 11.3 times larger than Achieve Life Sciences by market value ($6.50B vs $573.25M).

About Oruka Therapeutics

ORKA stock →

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 68 employees

About Achieve Life Sciences

QUIT stock →

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 28 employees

ORKA vs QUIT FAQ

Which is bigger, Oruka Therapeutics or Achieve Life Sciences?

Oruka Therapeutics (ORKA) is larger, with a market capitalization of $6.50B compared with $573.25M for Achieve Life Sciences (QUIT).

Are Oruka Therapeutics and Achieve Life Sciences in the same industry?

Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.

More comparisons